Centene Corporation (CNC) Stock

NYSE
HealthcareHealthcare Plans Website

CNC has an Alpha Score of 41 out of 100 (weak), computed on Nov 21, 2026 from 3 of 4 sub-scores. 14 members of Congress disclosed 50 trades in CNC since 2017: 33 purchases and 17 sales, most recently Tim Moore (sale, Aug 18, 2025). 7 of the hedge funds AlphaScala tracks reported CNC in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Marshall Wace's at $273.88M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 20, 2026. Its trailing P/E ratio is 24.0 and its net margin -3.3% (key statistics as of Nov 12, 2026).

$63.78
-2.74%
Last price
Source: Finnhub
Alpha Score
41
Weak

What is CNC's Alpha Score?

How it works →

Alpha Score of 41 reflects weak overall profile with moderate momentum, weak value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.

Momentum
53
Weak
Value
45
Weak
Quality
39
Weak

Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.

Computed Nov 21, 2026

A rules-based research rating, not a recommendation to buy or sell.

Which members of Congress traded Centene Corporation (CNC)?

Members
14
Disclosed trades
50
Purchases
33
Sales
17

Most recent: Tim Moore (sale, Aug 18, 2025); records start Jul 3, 2017.

PoliticianTrade dateTypeAmount
Tim Moore
R-NC · House
2025-08-18sale$100k – $250k
Tim Moore
R-NC · House
2025-08-08purchase$1k – $15k
Julia Letlow
R-LA · House
2025-08-08sale$1k – $15k
Tim Moore
R-NC · House
2025-08-07purchase$15k – $50k
Gil Cisneros
D-CA · House
2025-08-05purchase$1k – $15k
Tim Moore
R-NC · House
2025-07-30purchase$15k – $50k
Tim Moore
R-NC · House
2025-07-29purchase$15k – $50k
Tim Moore
R-NC · House
2025-07-22purchase$1k – $15k

From STOCK Act periodic transaction reports. House filings as of Nov 19, 2026.

Every member of Congress who traded CNC, with filing lags →

Which hedge funds own CNC?

From 13F filings
FundShares HeldPosition ValueChange vs prior Q
Marshall Wace4.41M$273.88M+246%
Renaissance Technologies
Jim Simons (founder)
3.93M$243.91M+79%
D.E. Shaw
David Shaw
2.89M$179.44M-45%
Greenlight Capital
David Einhorn
1.65M$102.57Mn/a
Point72
Steve Cohen
1.45M$90.15M+113%
Bridgewater Associates
Ray Dalio
1.30M$80.87M+236%
Millennium Management
Israel Englander
908K$56.41M-43%

13F holdings as of Sep 30, 2026

Explore all tracked funds →

Are Centene Corporation insiders buying or selling?

SEC Form 4 filings
90 days to Nov 20, 2026
Buys
0
Sells
1
Net $
-$3.8M
Unique insiders
1
DateInsiderRoleTypeSharesValue
Aug 26, 26Koster ChristopherSecretary & General CounselSELL56.5K$3.8M
Aug 18, 26Koster ChristopherSecretary & General CounselSELL47.6K$3.1M

SEC Form 4 filings as of Nov 20, 2026

See cluster-buy signals across all tickers →

What are CNC's key statistics?

P/E Ratio
23.97
EPS (TTM)
2.92
Beta
1.04
Net Margin
-3.25%
ROE
6.78%
Debt / Equity
0.87
52W High
$78.08
52W Low
$31.63

Key statistics as of Nov 12, 2026

How does CNC's valuation compare with the Healthcare sector?

MetricCNCHealthcare medianCompanies in median
P/E ratio24.028.8145
Net margin-3.25%3.62%218
Return on equity6.78%3.50%249

Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 21, 2026). P/E excludes loss-making companies.

What moved CNC recently?

AI-written from the data on this page

Centene shares gain 2.4%, approach 52-week high

Centene (CNC) rose 2.41% to $70.19 on Monday, closing within 3% of its 52-week high of $72.50. The managed-care provider reported a 17% year-over-year revenue increase in its latest quarter, though net margin remains negative at -3.3% and trailing EPS is -$10.44. The Alpha Score of 45.2 reflects strong momentum (82.8) offset by weak quality (33.2); value and sentiment scores were not computed. With the stock near the top of its 52-week range, the next quarterly earnings release will be a key catalyst for whether the uptrend can extend.

CNC price chart

Powered by TradingView

What does Centene Corporation do?

Centene Corporation is a leading American for-profit healthcare enterprise specializing in managed care services, primarily serving government-sponsored programs like Medicaid, Medicare, and the Health Insurance Marketplace. Headquartered in the Greater St. Louis area, it acts as an intermediary for both government-subsidized and privately insured healthcare, delivering affordable, high-quality coverage to nearly 28 million members across all 50 states—one in every 15 individuals nationwide. Founded in 1984 as a nonprofit Medicaid plan in Wisconsin by Elizabeth Brinn, the company evolved through strategic acquisitions, going public in 2001 and expanding under leaders like Michael Neidorff and current CEO Sarah London since 2022. Its core segments include Medicaid with local plans like Arizona Complete Health and Sunshine Health, commercial products for employer groups and individuals, and specialty services in behavioral health and pharmacy benefits. Ranked among the Fortune 500's top companies by revenue, Centene emphasizes a localized approach with culturally sensitive care, data-driven management, and innovation to address underserved populations, enhancing health equity and community wellness.

CEO
Ms. Sarah M. London
Employees
61,100
Market Cap
$35.00B
Ask about CNCAI research agent